文献速递头颈部肿瘤放疗

软腭剂量与接受根治性放疗的老年头颈癌患者正常组织毒性的关系

The role of the soft palate dose regarding normal tissue toxicities in older adults with head and neck cancer undergoing definitive radiotherapy.
PubMed 文献 · Radiat Oncol · 2024-04-30

本研究纳入2009至2019年在一家大型三级癌症中心接受根治性放疗的180例老年头颈鳞癌患者,中位年龄73岁,分析危及器官剂量与慢性毒性的相关性。多因素回归显示软腭剂量与慢性中度口干、中度味觉障碍及中度至重度吞咽困难均显著相关,并据此开发了正常组织并发症概率模型。

要点

  • 180例老年头颈鳞癌患者根治性放疗后,73例发生慢性中度口干,34例中度味觉障碍,59例中度至重度吞咽困难。
  • 多因素回归中软腭剂量与口干(OR=1.028)、味觉障碍(OR=1.022)、吞咽困难(OR=1.027)均显著相关。
  • 上咽缩肌与慢性吞咽困难显著相关(OR=1.030)。

核心结论

  • 作者认为,软腭剂量与老年头颈鳞癌根治性放疗患者的慢性中度口干、中度味觉障碍及中度至重度吞咽困难相关。
  • 作者指出,若经外部研究验证,应努力降低这些患者的软腭剂量。

研究设计与样本

  • 分析2009至2019年在一家大型三级癌症中心接受根治性放疗(单独或联合全身治疗)的老年头颈鳞癌患者。
  • 危及器官按国际共识指南勾画,基于放疗计划计算采用α/β=3 Gy的EQD2剂量。
  • 毒性按不良事件通用术语标准5.0版分级,行逻辑回归分析,并用自举法开发及内部验证NTCP模型。
  • 共180例患者符合纳入标准并进行分析,中位年龄73岁。

主要发现

  • 73例患者发生慢性中度口干(2级),34例发生中度味觉障碍(2级),59例发生中度至重度吞咽困难(2至3级)。
  • 多因素回归中软腭剂量与所有分析的毒性均显著相关:口干OR=1.028,味觉障碍OR=1.022,吞咽困难OR=1.027。
  • 上咽缩肌与慢性吞咽困难显著相关(OR=1.030)。
  • 连续开发的NTCP模型经内部验证可预测所分析的毒性,自举法校正乐观度后AUC:口干=0.64,味觉障碍=0.60,吞咽困难=0.64。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The number of older adults with head and neck squamous cell carcinoma (HNSCC) is continuously increasing. Older HNSCC patients may be more vulnerable to radiotherapy-related toxicities, so that extrapolation of available normal tissue complication probability (NTCP) models to this population may not be appropriate. Hence, we aimed to investigate the correlation between organ at risk (OAR) doses and chronic toxicities in older patients with HNSCC undergoing definitive radiotherapy. METHODS: Patients treated with definitive radiotherapy, either alone or with concomitant systemic treatment, between 2009 and 2019 in a large tertiary cancer center were eligible for this analysis. OARs were contoured based on international consensus guidelines, and EQD2 doses using α/ß values of 3 Gy for late effects were calculated based on the radiation treatment plans. Treatment-related toxicities were graded according to Common Terminology Criteria for Adverse Events version 5.0. Logistic regression analyses were carried out, and NTCP models were developed and internally validated using the bootstrapping method. RESULTS: A total of 180 patients with a median age of 73 years fulfilled the inclusion criteria and were analyzed. Seventy-three patients developed chronic moderate xerostomia (grade 2), 34 moderate dysgeusia (grade 2), and 59 moderate-to-severe (grade 2-3) dysphagia after definitive radiotherapy. The soft palate dose was significantly associated with all analyzed toxicities (xerostomia: OR = 1.028, dysgeusia: OR = 1.022, dysphagia: OR = 1.027) in the multivariable regression. The superior pharyngeal constrictor muscle was also significantly related to chronic dysphagia (OR = 1.030). Consecutively developed and internally validated NTCP models were predictive for the analyzed toxicities (optimism-corrected AUCs after bootstrapping: AUCxerostomia=0.64, AUCdysgeusia=0.60, AUCdysphagia=0.64). CONCLUSIONS: Our data suggest that the dose to the soft palate is associated with chronic moderate xerostomia, moderate dysgeusia and moderate-to-severe dysphagia in older HNSCC patients undergoing definitive radiotherapy. If validated in external studies, efforts should be undertaken to reduce the soft palate dose in these patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bitz HC, Sachpazidis I, Zou J, et al. The role of the soft palate dose regarding normal tissue toxicities in older adults with head and neck cancer undergoing definitive radiotherapy. Radiat Oncol. 2024. PMID: 38689338. doi:10.1186/s13014-024-02426-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。